New drug trial seeks to control advanced lung cancer in patients who have run out of options
NCT ID NCT06905197
Summary
This is the first study in people to test a new drug called DZD6008 for advanced non-small cell lung cancer (NSCLC) that has specific genetic changes (EGFR mutations). The main goals are to find a safe dose and see if the drug can shrink tumors. It will enroll about 140 adults whose cancer has progressed after standard treatments or who are newly diagnosed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Blacktown Hospital
ACTIVE_NOT_RECRUITINGBlacktown, New South Wales, 2148, Australia
-
Chris O'Brien Lifehouse
NOT_YET_RECRUITINGCamperdown, New South Wales, 2050, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Herbert Irving Comprehensive Cancer Center
RECRUITINGNew York, New York, 10032, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Virginia Cancer Specialist (NEXT Oncology-Virginia)
ACTIVE_NOT_RECRUITINGFairfax, Virginia, 22031, United States
Conditions
Explore the condition pages connected to this study.